2,400,605 Shares in Recursion Pharmaceuticals, Inc. $RXRX Bought by Renaissance Technologies LLC

Renaissance Technologies LLC purchased a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 1st quarter, Holdings Channel.com reports. The fund purchased 2,400,605 shares of the company’s stock, valued at approximately $7,370,000.

A number of other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its stake in shares of Recursion Pharmaceuticals by 18.6% during the 4th quarter. Vanguard Group Inc. now owns 47,187,759 shares of the company’s stock worth $192,998,000 after purchasing an additional 7,407,606 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Recursion Pharmaceuticals by 537.3% in the 4th quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after purchasing an additional 689,903 shares during the period. Lingotto Investment Management LLP lifted its stake in Recursion Pharmaceuticals by 34.2% in the 4th quarter. Lingotto Investment Management LLP now owns 4,931,057 shares of the company’s stock valued at $20,168,000 after purchasing an additional 1,255,980 shares during the last quarter. Norges Bank acquired a new stake in Recursion Pharmaceuticals in the 4th quarter valued at about $23,473,000. Finally, First Trust Advisors LP grew its holdings in Recursion Pharmaceuticals by 15.2% during the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after purchasing an additional 344,035 shares during the period. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Up 6.0%

Shares of RXRX stock opened at $3.18 on Tuesday. The firm has a 50 day moving average price of $3.32 and a two-hundred day moving average price of $3.49. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a market capitalization of $1.69 billion, a PE ratio of -2.65 and a beta of 1.03. Recursion Pharmaceuticals, Inc. has a 12-month low of $2.77 and a 12-month high of $7.18.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Wednesday, May 6th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.08. The company had revenue of $6.47 million for the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The firm’s revenue for the quarter was down 56.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.50) earnings per share. As a group, analysts predict that Recursion Pharmaceuticals, Inc. will post -0.99 earnings per share for the current year.

Insider Activity at Recursion Pharmaceuticals

In related news, CEO Najat Khan sold 23,588 shares of the business’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $3.58, for a total value of $84,445.04. Following the completion of the sale, the chief executive officer directly owned 2,175,796 shares in the company, valued at $7,789,349.68. The trade was a 1.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Blake Borgeson sold 40,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were sold at an average price of $3.96, for a total value of $158,400.00. Following the completion of the transaction, the director directly owned 6,218,287 shares in the company, valued at approximately $24,624,416.52. This represents a 0.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 101,937 shares of company stock valued at $381,374. 6.65% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on RXRX shares. Needham & Company LLC reissued a “buy” rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research note on Friday, July 17th. Morgan Stanley boosted their target price on Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a report on Thursday, May 14th. Finally, JPMorgan Chase & Co. dropped their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Two analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $8.10.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.